Cargando…

Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy

BACKGROUND: An increase in macular thickness due to fluid accumulation in the macula in patients with diabetes mellitus. Optical coherence tomography (OCT) has been shown to be highly reproducible in measuring macular thickness in normal individuals and diabetic patients. OCT can detect subtle chang...

Descripción completa

Detalles Bibliográficos
Autores principales: Demir, Mehmet, Oba, Ersin, Dirim, Burcu, Ozdal, Erhan, Can, Efe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623885/
https://www.ncbi.nlm.nih.gov/pubmed/23570310
http://dx.doi.org/10.1186/1471-2415-13-11
_version_ 1782265988179296256
author Demir, Mehmet
Oba, Ersin
Dirim, Burcu
Ozdal, Erhan
Can, Efe
author_facet Demir, Mehmet
Oba, Ersin
Dirim, Burcu
Ozdal, Erhan
Can, Efe
author_sort Demir, Mehmet
collection PubMed
description BACKGROUND: An increase in macular thickness due to fluid accumulation in the macula in patients with diabetes mellitus. Optical coherence tomography (OCT) has been shown to be highly reproducible in measuring macular thickness in normal individuals and diabetic patients. OCT can detect subtle changes of macular thickness. The aim of this study is to compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical retinopathy and normal controls, in order to assess possible increased macular thickness associated with diabetes mellitus. METHODS: Optical coherence tomography (OCT) measurements were performed in 124 eyes of 62 subjects with diabetes mellitus without clinically retinopathy (study group: 39 female, 23 male, mean age: 55.06 ± 9.77 years) and in 120 eyes of 60 healthy subjects (control group: 35 female, 25 male, mean age: 55.78 ± 10.34 years). Blood biochemistry parameters were analyzed in all cases. The data for central macular thickness (at 1 mm) and the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1c) were compared in both groups. RESULTS: The mean central macular thickness was 232.12 ±24.41 μm in the study group and 227.19 ± 29.94 μm in the control group. The mean HbA1c level was 8.92 ± 2.58% in the study group and 5.07 ± 0.70% in the control group (p=0.001). No statistically significant relationship was found between CMT, HbA1c, and fasting plasma glucose level in either group (p=0.05). CONCLUSIONS: Central macular thickness was not significantly thicker in patients with type 2 diabetes without clinical retinopathy than in healthy subjects.
format Online
Article
Text
id pubmed-3623885
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36238852013-04-13 Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy Demir, Mehmet Oba, Ersin Dirim, Burcu Ozdal, Erhan Can, Efe BMC Ophthalmol Research Article BACKGROUND: An increase in macular thickness due to fluid accumulation in the macula in patients with diabetes mellitus. Optical coherence tomography (OCT) has been shown to be highly reproducible in measuring macular thickness in normal individuals and diabetic patients. OCT can detect subtle changes of macular thickness. The aim of this study is to compare central macular thickness (CMT) of diabetic patients with type 2 diabetes without clinical retinopathy and normal controls, in order to assess possible increased macular thickness associated with diabetes mellitus. METHODS: Optical coherence tomography (OCT) measurements were performed in 124 eyes of 62 subjects with diabetes mellitus without clinically retinopathy (study group: 39 female, 23 male, mean age: 55.06 ± 9.77 years) and in 120 eyes of 60 healthy subjects (control group: 35 female, 25 male, mean age: 55.78 ± 10.34 years). Blood biochemistry parameters were analyzed in all cases. The data for central macular thickness (at 1 mm) and the levels of the fasting plasma glucose and glycosylated hemoglobin (HbA1c) were compared in both groups. RESULTS: The mean central macular thickness was 232.12 ±24.41 μm in the study group and 227.19 ± 29.94 μm in the control group. The mean HbA1c level was 8.92 ± 2.58% in the study group and 5.07 ± 0.70% in the control group (p=0.001). No statistically significant relationship was found between CMT, HbA1c, and fasting plasma glucose level in either group (p=0.05). CONCLUSIONS: Central macular thickness was not significantly thicker in patients with type 2 diabetes without clinical retinopathy than in healthy subjects. BioMed Central 2013-04-09 /pmc/articles/PMC3623885/ /pubmed/23570310 http://dx.doi.org/10.1186/1471-2415-13-11 Text en Copyright © 2013 Demir et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Demir, Mehmet
Oba, Ersin
Dirim, Burcu
Ozdal, Erhan
Can, Efe
Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy
title Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy
title_full Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy
title_fullStr Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy
title_full_unstemmed Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy
title_short Cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy
title_sort cental macular thickness in patients with type 2 diabetes mellitus without clinical retinopathy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3623885/
https://www.ncbi.nlm.nih.gov/pubmed/23570310
http://dx.doi.org/10.1186/1471-2415-13-11
work_keys_str_mv AT demirmehmet centalmacularthicknessinpatientswithtype2diabetesmellituswithoutclinicalretinopathy
AT obaersin centalmacularthicknessinpatientswithtype2diabetesmellituswithoutclinicalretinopathy
AT dirimburcu centalmacularthicknessinpatientswithtype2diabetesmellituswithoutclinicalretinopathy
AT ozdalerhan centalmacularthicknessinpatientswithtype2diabetesmellituswithoutclinicalretinopathy
AT canefe centalmacularthicknessinpatientswithtype2diabetesmellituswithoutclinicalretinopathy